Research Paper Volume 13, Issue 17 pp 21102—21121
Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
Figure 5. The ITK expression is regulated by BGB-3111 and ibrutinib in the Jurkat T-cells. (A) The ITK expression in the Jurkat T-cells treated with BGB-3111 and ibrutinib at the same dose of 2 μM for 0–48 h. (B) The percentage of inhibition rate of the ITK protein in the Jurkat T-cells treated with BGB-3111 and ibrutinib. **p < 0.01.